Mireille Vankemmelbeke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mireille Vankemmelbeke has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Lindy Durrant
Scancell Ltd., Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom
49 shared publications - Bryony Heath
Scancell Ltd., Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom
34 shared publications - Bubacarr G. Kaira
Scancell Ltd., Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom
34 shared publications - Dhruma Thakker
Scancell Ltd., Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom
34 shared publications - Elena Dubinina
Scancell Ltd., Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom
34 shared publications - Foram Dave
Scancell Ltd., Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom
34 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Glycolipid binding validation and IHC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Glycolipid binding validation and IHC
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 11 from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Individual tumour growth curves, dosing regimen study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 11 from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Individual tumour growth curves, dosing regimen study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Method from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Protein sequence and generation of SC134-TCB
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Method from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Protein sequence and generation of SC134-TCB
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 7 from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Serum levels of SC134-TCB in NSG mice
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 7 from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Serum levels of SC134-TCB in NSG mice
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Target-dependent multifunctional cytokine production
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models
Target-dependent multifunctional cytokine production